drugset / Trial / NCT07407634
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
RandomizedSequentialQuadruple-blindTreatment
Summary
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.
Timeline
- Start
- 2026-03-25
- Primary completion
- 2027-02-26
- Completion
- 2027-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XTYW007 | Unknown | 0.2 mg | — |
| Subject | XTYW007 | Unknown | 0.6 mg | — |
| Subject | XTYW007 | Unknown | 1.5 mg | — |
| Subject | XTYW007 | Unknown | 3 mg | — |
| Subject | XTYW007 | Unknown | 6 mg | — |
| Subject | XTYW007 | Unknown | 10 mg | — |
| Subject | XTYW007 | Unknown | 15 mg | — |
| Subject | XTYW007 | Unknown | 20 mg | — |